Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03573089 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

Study acronym: PHOSPHATE
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 115 → 126 locationsv23
  2. Study sites: 99 to 115v22
  3. Study sites: 86 to 99v21
  4. Primary completion date: Dec 31, 2023 to Dec 31, 2027
    • Study completion date: Dec 31, 2025 to Dec 31, 2028
    v20
  5. Study sites: 85 to 86v19
Show 17 earlier versionsHide 17 earlier versions
  1. Study sites: 75 to 85v18
  2. Study sites: 71 to 75v17
  3. Study sites: 62 to 71v16
  4. Study sites: 55 to 62v15
  5. Study sites: 49 to 55v14
  6. Study sites revised (49)v13
  7. Study sites: 48 to 49v12
  8. Study sites revised (48)v11
  9. Site details revised at 4 of 48 sitesv10
  10. Study sites: 32 to 48v9
  11. Study sites: 31 to 32v8
  12. Study sites: 32 to 31v7
  13. Study sites: 28 to 32
    • Collaborators: 3 to 4
    v6
  14. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 1, 2019 to Dec 10, 2019
    • Study sites: 0 to 28
    • Eligibility criteria expanded, about 5 words
    v5
  15. Start date: Jan 1, 2019 to Jul 1, 2019v4
  16. Enrollment target: 600 to 3600v3 Show 5 more changesShow less
    • Study completion date: Dec 31, 2024 to Dec 31, 2025
    • Secondary endpoints: 15 to 3
    • Collaborators: 1 to 3
    • Eligibility criteria shortened, about 3 words
    • Study description shortened, about 5 words
  17. Primary completion date: Aug 31, 2021 to Dec 31, 2023
    • Study completion date: Aug 31, 2021 to Dec 31, 2024
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.
Trial Details
NCT Number NCT03573089
Lead Sponsor The University of Queensland
Collaborators: National Health and Medical Research Council, Australia, Applied Health Research Centre, Cambridge University Hospitals NHS Foundation Trust, University of Otago
Conditions
(from sponsor)		 Kidney Failure, Chronic, Hyperphosphatemia
Related terms Hyperphosphatemia, Kidney Failure, Chronic
Enrollment 3,600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov